Advocacy intelligence hub — real-time data for patient organizations
Nulibry: FDA approved
to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Nulibry
Origin Biosciences, Inc.
Nulibry
(fosdenopterin)Orphan drugOrigin Biosciences, Inc.
12.1 Mechanism of Action Patients with MoCD Type A have mutations in the MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermedi...
Browse all Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C news →
View all Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C specialists →